Basic Information
| LncRNA/CircRNA Name | ZEB1-AS1 |
| Synonyms | NA |
| Region | GRCh38_10:31206278-31320447 |
| Ensemble | ENSG00000237036 |
| Refseq | NR_024284 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | NSCLC tissues, NSCLC cell lines (PC9, H1299, H1975, H460, and A-427) and a normal human bronchial epithelial cell line (16HBE) |
| Expression Pattern | up-regulated |
| Function Description | ZEB1-AS1 was significantly up-regulated in NSCLC tissues compared with normal samples. ZEB1-AS1 overexpression was significantly associated with advanced tumor, lymph node, and metastases (TNM) stage and tumor size, as well as poorer overall survival. Moreover, ZEB1-AS1 knockdown inhibited NSCLC cell proliferation and migration, and promoted cell apoptosis. In addition, a chromatin immunoprecipitation assay revealed that ZEB1-AS1 interacted with STAT3, thereby repressing ID1 expression. Furthermore, rescue experiments indicated that ZEB1-AS1 functioned as an oncogene partly by repressing ID1 in NSCLC cells. |
| Pubmed ID | 30626729 |
| Year | 2019 |
| Title | ZEB1-AS1 is associated with poor prognosis in non-small-cell lung cancer and influences cell migration and apoptosis by repressing ID1. |
External Links
| Links for ZEB1-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |